Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Zenicor Medical Systems AB's annualizedNet Income for the quarter that ended in Jun. 2026 was kr0.42 Mil. Zenicor Medical Systems AB's average total tangible assets for the quarter that ended in Jun. 2026 was kr41.38 Mil. Therefore, Zenicor Medical Systems AB's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 1.01%.
The historical rank and industry rank for Zenicor Medical Systems AB's Return-on-Tangible-Asset or its related term are showing as below:
XSAT:ZENI'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -24.41 Med: -8.44 Max: 7.1
Current: 2.69
During the past 13 years, Zenicor Medical Systems AB's highest Return-on-Tangible-Asset was 7.10%. The lowest was -24.41%. And the median was -8.44%.
XSAT:ZENI's Return-on-Tangible-Asset is ranked better than 56.4% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.96
vs XSAT:ZENI: 2.69
Zenicor Medical Systems AB (XSAT:ZENI) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Zenicor Medical Systems AB Return-on-Tangible-Asset Related Terms
Zenicor Medical Systems AB Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenicor Medical Systems AB Return-on-Tangible-Asset Chart
XSAT:ZENI vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Zenicor Medical Systems AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenicor Medical Systems AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zenicor Medical Systems AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Zenicor Medical Systems AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 1.01% mean?
Zenicor Medical Systems AB (XSAT:ZENI) has a Return-on-Tangible-Asset of 1.01% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Zenicor Medical Systems AB and its competitors. According to the industry distribution chart, Zenicor Medical Systems AB ranks #371 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 43.6%.
Is Zenicor Medical Systems AB's Return-on-Tangible-Asset too high?
Zenicor Medical Systems AB's current Return-on-Tangible-Asset is 1.01%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.96. Zenicor Medical Systems AB's value of 1.01% is 5.2% above this industry median. Based on the distribution chart, Zenicor Medical Systems AB ranks #371 out of 851 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zenicor Medical Systems AB has a GF Score™ of 45/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zenicor Medical Systems AB's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zenicor Medical Systems AB ranks #371 out of 851 companies for Return-on-Tangible-Asset. This puts Zenicor Medical Systems AB in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.96. Zenicor Medical Systems AB's value of 1.01% is 5.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.96, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenicor Medical Systems AB's current Return-on-Tangible-Asset of 1.01% is 5.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Zenicor Medical Systems AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenicor Medical Systems AB's current Return-on-Tangible-Asset is 1.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenicor Medical Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Zenicor Medical Systems AB (XSAT:ZENI) is currently considered Fairly Valued. The stock's GF Value™ is kr1.03, compared to a current price of kr0.95 — trading 8.3% below its estimated fair value. The current Return-on-Tangible-Asset is 1.01% and 5.2% above the Medical Devices & Instruments industry median of 0.96. Zenicor Medical Systems AB's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Zenicor Medical Systems AB (XSAT:ZENI), the current Return-on-Tangible-Asset is 1.01% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenicor Medical Systems AB (XSAT:ZENI) Overvalued in 2026?
Based on GuruFocus' analysis, Zenicor Medical Systems AB stock appears to be undervalued.
The current stock price of kr0.95 is trading 8.3% below its estimated GF Value™ of kr1.03.
GuruFocus considers Zenicor Medical Systems AB to be Fairly Valued.
Key valuation signals for XSAT:ZENI:
Return-on-Tangible-Asset: 1.01%
GF Value™: kr1.03 vs. price of kr0.95 (8.3% below fair value)
Industry Position: 5.2% above the Medical Devices & Instruments median (#371 of 851)
No single metric tells the full story. See the XSAT:ZENI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ZENI has been successfully added to your 
